Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition.
Saved in:
| Title: | Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition. |
|---|---|
| Authors: | Fogal V; Oncology Safety, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.; Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK., Michopoulos F; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Jarnuczak AF; Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Hamza GM; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA., Harlfinger S; DMPK, Oncology R&D, AstraZeneca, Cambridge, UK., Davey P; Chemistry, Oncology R&D AstraZeneca, Cambridge, UK., Hulme H; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK., Atkinson SJ; Chemistry, Oncology R&D AstraZeneca, Cambridge, UK., Gabrowski P; Biological Insights Knowledge Graph, R&D IT, AstraZeneca, Barcelona, Spain., Cheung T; Oncology R&D, AstraZeneca, R&D Boston, Waltham, USA., Grondine M; Oncology R&D, AstraZeneca, R&D Boston, Waltham, USA., Hoover C; Oncology Safety Pathology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA., Rose J; Animal Science & Technologies, R&D, AstraZeneca, Cambridge, UK., Bray C; Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK., Foster AJ; Regulatory Toxicology and Safety Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK., Askin S; Advanced Drug Delivery, Pharmaceutical Sci, R&D, AstraZeneca, Cambridge, UK., Majumder MM; Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Fitzpatrick P; Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Miele E; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA., Macdonald R; Animal Science & Technologies, R&D, AstraZeneca, Cambridge, UK., Keun HC; Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK., Coen M; Oncology Safety, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK. muireann.coen@astrazeneca.com. |
| Source: | Archives of toxicology [Arch Toxicol] 2024 Aug; Vol. 98 (8), pp. 2589-2603. Date of Electronic Publication: 2024 May 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0417615 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0738 (Electronic) Linking ISSN: 03405761 NLM ISO Abbreviation: Arch Toxicol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0738 |
|---|---|
| DOI: | 10.1007/s00204-024-03771-w |
